Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALECSAT - CytoVac

Drug Profile

ALECSAT - CytoVac

Alternative Names: ALECSAT

Latest Information Update: 23 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytoVac
  • Class Cell therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoma; Glioblastoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Sarcoma
  • Phase I/II Triple negative breast cancer
  • Phase I Pancreatic cancer; Prostate cancer

Most Recent Events

  • 23 Jul 2022 Phase I/II development in Triple-negative-breast cancer (Metastatic disease, Adjunctive treatment, Late-stage disease) is ongoing in Denmark (IV) (NCT04609215) (EudraCT2019-001420-34)
  • 13 Jun 2022 ALECSAT is still in phase I trials for pancreatic cancer and prostate cancer in Denmark (CytoVac pipeline, June 2022)
  • 13 Jun 2022 ALECSAT - CytoVac is available for licensing for pancreatic cancer and prostate cancer as of 13 Jun 2022 (https://cytovac.com/pipeline-clinical-data/pipeline/)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top